Your browser doesn't support javascript.
loading
How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?
Gauthier, S; Leuzy, A; Rosa-Neto, P.
Affiliation
  • Gauthier S; McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Que., Canada.
Neurodegener Dis ; 13(2-3): 197-9, 2014.
Article in En | MEDLINE | ID: mdl-23942173
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Randomized Controlled Trials as Topic / Outcome Assessment, Health Care / Neuroprotective Agents / Translational Research, Biomedical / Alzheimer Disease Type of study: Clinical_trials Limits: Humans Language: En Journal: Neurodegener Dis Journal subject: NEUROLOGIA Year: 2014 Type: Article Affiliation country: Canada
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Randomized Controlled Trials as Topic / Outcome Assessment, Health Care / Neuroprotective Agents / Translational Research, Biomedical / Alzheimer Disease Type of study: Clinical_trials Limits: Humans Language: En Journal: Neurodegener Dis Journal subject: NEUROLOGIA Year: 2014 Type: Article Affiliation country: Canada